Simultaneous hyperbaric oxygen therapy during systemic chemotherapy reverses chemotherapy-induced peripheral neuropathy by inhibiting TLR4 and TRPV1 activation in the central and peripheral nervous system.

What Researchers Did

Researchers investigated the effects of simultaneous hyperbaric oxygen therapy (SHBOT) during paclitaxel chemotherapy on chemotherapy-induced peripheral neuropathy (CIPN) in a rat model.

What They Found

In 24 rats, simultaneous HBOT during paclitaxel chemotherapy significantly alleviated CIPN symptoms and inhibited their deterioration in mechanical and thermal behavior tests. Immunofluorescence staining showed that SHBOT early and significantly downregulated upregulated TLR4, TRPV1, and microglial activation in the spinal cord and dorsal root ganglions of treated rats.

What This Means for Canadian Patients

While this study was conducted in rats, it suggests that hyperbaric oxygen therapy administered concurrently with chemotherapy could potentially reduce chemotherapy-induced peripheral neuropathy. This approach might offer a future strategy to mitigate a common and debilitating side effect for Canadian cancer patients undergoing chemotherapy.

Canadian Relevance

This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.

Study Limitations

A significant limitation of this study is that its findings are based on a rat model, meaning direct applicability to human patients is not yet established.